...
首页> 外文期刊>The Journal of dermatology >Durvalumab-induced de novo annular psoriasiform drug eruption successfully treated with a combination of narrowband ultraviolet B phototherapy and topical treatment
【24h】

Durvalumab-induced de novo annular psoriasiform drug eruption successfully treated with a combination of narrowband ultraviolet B phototherapy and topical treatment

机译:Durvalumab-诱导De Novo环形牛皮癣药喷发成功用窄带紫外线B光疗法和局部处理的组合治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Immune checkpoint inhibitors, including anti-programmed death 1 and anti-programmed death ligand 1, have become prominent treatment options for various types of cancers. However, immune checkpoint inhibitors are associated with various cutaneous adverse events, one of which is psoriasiform drug eruption. Some cases of psoriasiform drug eruption can only be controlled through the cessation of immune checkpoint inhibitors and administration of systemic immunosuppressants, such as corticosteroids and methotrexate. However, no clear guideline is available on the management of this specific rash, and the use of systemic immunosuppressants is contraindicated in selected conditions. In this article, we report a case of annular psoriasiform drug eruption induced by an anti-programmed death ligand 1 monoclonal antibody, durvalumab. The patient responded well to the combination of phototherapy and topical treatment, which allowed continuation of durvalumab treatment without concomitant systemic immunosuppressants in a 2-year follow up.
机译:免疫检查点抑制剂,包括抗程序性死亡1和抗程序性死亡配体1,已成为各种癌症的重要治疗选择。然而,免疫检查点抑制剂与各种皮肤不良事件有关,其中之一是银屑病样药疹。一些银屑病样药疹病例只能通过停止使用免疫检查点抑制剂和全身免疫抑制剂(如皮质类固醇和甲氨蝶呤)来控制。然而,对于这种特殊皮疹的治疗尚无明确的指导方针,在某些情况下禁止使用全身免疫抑制剂。在本文中,我们报告了一例由抗程序性死亡配体1单克隆抗体durvalumab诱发的环状银屑病样药疹。患者对光疗和局部治疗的组合反应良好,在2年的随访中,可以在不同时使用全身免疫抑制剂的情况下继续使用杜瓦鲁单抗治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号